Meds & Supplements, News & Research, Treatment

UK Approves Migraine Drug for Marketing

British regulators have approved Pozen’s MT 100, a drug that combines naproxen (which is what’s in Aleve) and metoclopramide (Reglan, an anti-nausea med), for marketing in the UK. migraineurs without nausea are the drug’s target market. Yes, you read that right — migraineurs without nausea. Metoclopramide is said to increase the speed by which the body absorbs naproxen, bringing pain relief more quickly.

Pozen stopped developing MT 100 for sale in the US in August after an FDA advisory panel raised concerns about possible side effects. The panel said that the risk of tardive dyskinesia, a neurological disorder where patients suffer from involuntary movements, was greater than the drug’s potential benefits. Furthermore, the FDA wasn’t convinced of the necessity of this combination of drugs in one pill.

Leave a Reply

Your email address will not be published. Required fields are marked *